Gilbert Thompson was born in 1932 and educated at Downside and St. Thomas’s Hospital Medical School, London, where he qualified in 1956. After military service he joined the Royal Postgraduate Medical School, Hammersmith Hospital, London in 1963 where he remained for most of his career except for periods spent at the Massachusetts General Hospital, Boston (1966-7), the Methodist Hospital, Houston (1972-3) and the Royal Victoria Hospital, Montreal (1981-2), where he was Visiting Professor and recipient of the Lucien Award. He was also a Visiting Professor at the Mayo Clinic in 1997. He led the Medical Research Council Lipoprotein Team at Hammersmith until his retirement in 1998 and was Professor of Clinical Lipidology at the Imperial College School of Medicine, Hammersmith Hospital, where he was Honorary Consultant Physician in charge of the Lipid Clinic. Currently he is Emeritus Professor in Clinical Lipidology at the Hammersmith Campus of Imperial College.
He is a Past Chairman of the British Atherosclerosis Society, the British Hyperlipidaemia Association and the Forum on Lipids in Clinical Medicine of the Royal Society of Medicine and is a Distinguished Fellow of the International Atherosclerosis Society. He has served on the British Heart Foundation Grants Committee and the Morgagni Prize Committee of the University of Padua and was a Past Chairman and Trustee of the Simon Broome Heart Research Trust. He has been an Advisor to the British National Formulary, an Associate Editor of the Journal of Lipid Research and was the first Editor of Current Opinion in Lipidology. He is the author of eight books, 29 chapters and more than 300 papers, mainly in the field of lipoprotein metabolism and atherosclerosis.
Thompson GR, 2018, Atherosclerosis in cholesterol-fed rabbits and in homozygous and heterozygous LDL receptor-deficient humans, Atherosclerosis, Vol:276, ISSN:0021-9150, Pages:148-154
et al., 2018, Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol, European Heart Journal, Vol:39, ISSN:0195-668X, Pages:1162-1168
Thompson G, 2017, Limitations of cholesterol lowering with PCSK9 inhibitors, The Lancet Diabetes & Endocrinology, Vol:5, ISSN:2213-8587, Pages:241-243
et al., 2016, HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom, Atherosclerosis, Vol:255, ISSN:0021-9150, Pages:128-139
et al., 2018, HYPERCHOLESTEROLEMIA WITH LOW VERSUS HIGH LIKELIHOOD OF POLYGENIC ORIGIN: A SINGLE CENTRE EXPERIENCE, HEART UK 32nd Annual Medical and Scientific Conference on Hot Topics in Atheroscloerosis and Cardiovascular Disease, ELSEVIER IRELAND LTD, Pages:E7-E7, ISSN:1567-5688